• endometrial cancer - (neo)adjuvant (NA) 1
• esophageal cancer (EC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• camrelizumab based treatment
• camrelizumab alone
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus SoC
• Tislelizumab
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs platin and fluoropyrimidine
• vs cisplatin plus 5FU
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs durvalumab based treatment
• vs durvalumab alone
• vs nivolumab based treatment
• vs nivolumab alone
• vs non active control
• vs no additional treatment
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)